In molecular biology, the five-prime cap (5â² cap) is a specially altered nucleotide on the 5â² end of some primary transcripts such as precursor messenger RNA. This process, known as mRNA capping, is highly regulated and vital in the creation of stable and mature messenger RNA able to undergo translation during protein synthesis. Mitochondrial mRNA and chloroplastic mRNA are not capped.
In eukaryotes, the 5â² cap (cap-0), found on the 5â² end of an mRNA molecule, consists of a guanine nucleotide connected to mRNA via an unusual 5â² to 5â² triphosphate linkage. This guanosine is methylated on the 7 position directly after capping in vivo by a methyltransferase. It is referred to as a 7-methylguanylate cap, abbreviated m<sup>7</sup>G. The Cap-0 is the base cap structure, however, the first and second transcribed nucleotides can also be 2' O-methylated, leading to the Cap-1 and Cap-2 structures, respectively. This is more common in higher eukaryotes and thought to be part of the innate immune system to recognize mRNAs from other organisms.
In multicellular eukaryotes and some viruses, further modifications can be made, including the methylation of the 2â² hydroxy-groups of the first two ribose sugars of the 5â² end of the mRNA. cap-1 has a methylated 2â²-hydroxy group on the first ribose sugar, while cap-2 has methylated 2â²-hydroxy groups on the first two ribose sugars, shown on the right. The 5â² cap is chemically similar to the 3â² end of an RNA molecule (the 5â² carbon of the cap ribose is bonded, and the 3â² unbonded). This provides significant resistance to 5â² exonucleases.
Small nuclear RNAs contain unique 5â²-caps. Sm-class snRNAs are found with 5â²-trimethylguanosine caps, while Lsm-class snRNAs are found with 5â²-monomethylphosphate caps.
In bacteria, and potentially also in higher organisms, some RNAs are capped with NAD<sup>+</sup>, NADH, or 3â²-dephospho-coenzyme A.
In all organisms, mRNA molecules can be decapped in a process known as messenger RNA decapping. This is usually followed by degradation of the mRNA.
The starting point for capping with 7-methylguanylate is the unaltered 5â² end of an RNA molecule, which terminates at a triphosphate group. This features a final nucleotide followed by three phosphate groups attached to the 5â² carbon. The capping process is initiated before the completion of transcription, as the nascent pre-mRNA is being synthesized.
The mechanism of capping with NAD<sup>+</sup>, NADH, or 3â²-dephospho-coenzyme A is different. Capping with NAD<sup>+</sup>, NADH, or 3â²-dephospho-coenzyme A is accomplished through an "ab initio capping mechanism," in which NAD<sup>+</sup>, NADH, or 3â²-desphospho-coenzyme A serves as a "non-canonical initiating nucleotide" (NCIN) for transcription initiation by RNA polymerase and thereby directly is incorporated into the RNA product. Both bacterial RNA polymerase and eukaryotic RNA polymerase II are able to carry out this "ab initio capping mechanism".
For capping with 7-methylguanylate, the capping enzyme complex (CEC) binds to RNA polymerase II before transcription starts. As soon as the 5â² end of the new transcript emerges from RNA polymerase II, the CEC carries out the capping process (this kind of mechanism ensures capping, as with polyadenylation). The enzymes for capping can only bind to RNA polymerase II, ensuring specificity to only these transcripts, which are almost entirely mRNA.
Capping with NAD<sup>+</sup>, NADH, or 3â²-dephospho-coenzyme A is targeted by promoter sequence. Capping with NAD+, NADH, or 3â²-dephospho-coenzyme A occurs only at promoters that have certain sequences at and immediately upstream of the transcription start site and therefore occurs only for RNAs synthesized from certain promoters.
The 5â² cap has four main functions:
Nuclear export of RNA is regulated by the cap binding complex (CBC), which binds exclusively to 7-methylguanylate-capped RNA. The CBC is then recognized by the nuclear pore complex and exported. Once in the cytoplasm after the pioneer round of translation, the CBC is replaced by the translation factors eIF4E and eIF4G of the eIF4F complex. This complex is then recognized by other translation initiation machinery including the ribosome.
Capping with 7-methylguanylate prevents 5â² degradation in two ways. First, degradation of the mRNA by 5â² exonucleases is prevented (as mentioned above) by functionally looking like a 3â² end. Second, the CBC and eIF4E/eIF4G block the access of decapping enzymes to the cap. This increases the half-life of the mRNA, essential in eukaryotes as the export and translation processes take significant time.
Decapping of a 7-methylguanylate-capped mRNA is catalyzed by the decapping complex made up of at least Dcp1 and Dcp2, which must compete with eIF4E to bind the cap. Thus the 7-methylguanylate cap is a marker of an actively translating mRNA and is used by cells to regulate mRNA half-lives in response to new stimuli. Undesirable mRNAs are sent to P-bodies for temporary storage or decapping, the details of which are still being resolved.
The mechanism of 5â² proximal intron excision promotion is not well understood, but the 7-methylguanylate cap appears to loop around and interact with the spliceosome in the splicing process, promoting intron excision.